2022
DOI: 10.1016/j.apmt.2022.101397
|View full text |Cite
|
Sign up to set email alerts
|

Advances in carbon nanomaterials for immunotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
34
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

4
4

Authors

Journals

citations
Cited by 23 publications
(34 citation statements)
references
References 165 publications
0
34
0
Order By: Relevance
“…Pre-clinical research seeks to clarify the mechanisms of action, drug delivery systems, and treatment safety, as well as the efficacy and stability of nanomedicines in cancer therapy, in order to prevent potentially expensive limitations that might hinder future investments and developments [ 197 , 198 ]. As a result, selecting suitable pre-clinical models is critical for understanding the effects of nanomedicine therapies on the immune system and lowering the risks for clinical applications.…”
Section: Challenges and Opportunitiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Pre-clinical research seeks to clarify the mechanisms of action, drug delivery systems, and treatment safety, as well as the efficacy and stability of nanomedicines in cancer therapy, in order to prevent potentially expensive limitations that might hinder future investments and developments [ 197 , 198 ]. As a result, selecting suitable pre-clinical models is critical for understanding the effects of nanomedicine therapies on the immune system and lowering the risks for clinical applications.…”
Section: Challenges and Opportunitiesmentioning
confidence: 99%
“…As a result, selecting suitable pre-clinical models is critical for understanding the effects of nanomedicine therapies on the immune system and lowering the risks for clinical applications. Although rodent models are the most commonly used to research immune responses to treatments, there are significant differences between them and human immune responses in terms of immune cell development, activation, complexity, proliferation, and function [ 198 ]. Moreover, the commonly used mouse xenograph models tend to overestimate nanomedicine’s effectiveness due to increased accumulation at the tumor site induced by an exaggerated EPR effect [ 197 ].…”
Section: Challenges and Opportunitiesmentioning
confidence: 99%
“…Bioaccumulation in the major organs or tissues, impurities/contamination, dosage, ROS generation, and particle size are some of the biggest concerns regarding the use of nano-scaled materials [ 125 , 126 , 127 , 128 ]. Graphene has been widely researched for biomedical applications and has demonstrated great properties for its use in cancer treatment, despite controversial results regarding its biosafety [ 126 , 129 ]. BP has been demonstrated to have higher biocompatibility than graphene, especially when incorporated in biopolymers or surface-functionalized [ 130 ].…”
Section: 2d Nanomaterials Polymeric Composites For Biomedical Applica...mentioning
confidence: 99%
“…Thus, immobilization on other materials has been proposed to decrease cellular internalization [25] . Graphene-based materials (GBM) are promising particles with larger sizes –hundreds to thousands of nanometers– for reduced internalization, showing good biocompatibility at high concentrations in vitro and in vivo , as well as biodegradation by neutrophils or the human enzyme myeloperoxidase [26,27] . In particular, reduced graphene oxide (rGO) is a popular GBM with greater hemocompatibility than graphene oxide [28,29] that has been shown to promote myogenic differentiation with low reduction in cell viability [13] .…”
Section: Introductionmentioning
confidence: 99%